Novo Nordisk A/S (NYSE:NVO) decision to use "Novo" as its day-to-day name is part of a broader attempt by CEO Mike Doustdar to reset the company's culture and sharpen its competitive focus. The rebrand comes as Novo tries to regain momentum in obesity drugs after losing ground to Eli Lilly. Doustdar's new "Novo Way" emphasizes customer focus, competitiveness, clarity, and care, reflecting his view that the company needs to become more responsive to patients and consumers rather than relying primarily on its historical position in the market. Reuters similarly describes the move as a cultural reset aimed at reclaiming competitiveness.
Publicznie pokazujemy glowna mysl. Utworz darmowe konto, aby czytac caly artykul, zapisac go, omowic i polaczyc z kontekstem rynkowym oraz OSINT.